The impact of neutropenia severity in the setting of recent chemotherapy on mortality in sepsis
- 25 December 2025
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (2) , 347-354
Abstract
Background Sepsis and septic shock are major causes of non-relapse mortality in cancer patients, with chemotherapy-induced neutropenia increasing infection risk. The prognostic impact of neutropenia remains unclear across cancer subtypes. Patients and methods We conducted a retrospective cohort study using the TriNetX Research Network, comprising deidentified data from over 141 million patients across 105 U.S. health care organizations. Adults with select solid cancers who received chemotherapy and developed severe sepsis with septic shock from 2013 to 2024 were included. Patients were stratified by neutropenia severity (< 0.5 × 103/µL vs. 0.5–1.5 × 103/µL), and propensity score matching was applied to balance demographics, comorbidities, and treatment variables. Outcomes including short- and long-term mortality, organ failure, bacteremia, and immune-related adverse events were assessed using Kaplan–Meier survival analysis. Results Among 1083 eligible patients (184 severe, 899 mild–moderate neutropenia), severe neutropenia was associated with significantly worse survival at all timepoints, with median survival of 13 days versus 106 days and hazard ratios of 1.56–2.03 from 30 days to 1 year (all p < 0.001). Secondary outcomes showed no difference in immune-related adverse events, a nonsignificant trend toward increased organ failure, and higher rates of bacteremia in the severe neutropenia cohort. Conclusions Greater severity of chemotherapy-associated neutropenia is linked to worse short-term survival and increased complications in cancer patients with septic shock. Stratifying by neutrophil count bands revealed that severe neutropenia (< 0.5 × 103/µL) independently predicts poorer outcomes, emphasizing its value for risk stratification and guiding clinical management.Keywords
This publication has 22 references indexed in Scilit:
- Cancer and sepsisClinical Science, 2023
- All-cause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysisSupportive Care in Cancer, 2022
- Evaluation and Management of Patients With Isolated NeutropeniaSeminars in Hematology, 2013
- Critically ill patients with cancer and sepsis: Clinical course and prognostic factorsJournal of Critical Care, 2012
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Impact of neutropenia on the outcomes of critically ill patients with cancer: a matched case–control studyAnnals of Oncology, 2011
- Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapySupportive Care in Cancer, 2010
- Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and OncologyEuropean Journal of Cancer, 2009
- Identification of children presenting with fever in chemotherapy‐induced neutropenia at low risk for severe bacterial infectionMedical and Pediatric Oncology, 2003
- The economics of febrile neutropenia: implications for the use of colony-stimulating factorsEuropean Journal of Cancer, 1998